The study for the efficacy of the combine therapy with proton pump inhibitor and rebamipide for the post-endoscopic submucosal dissection (ESD) gastric ulcer

The study for the efficacy of the combine therapy with proton pump inhibitor and rebamipide for the post-endoscopic submucosal dissection (ESD) gastric ulcer - The combined therapy with proton pump inhibitor and rebamipide for post-ESD gastric ulcer

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000007435

Enrollment

140

Registered

2012-03-05

Start date

2010-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastric ulcer

Interventions

rabeprazole 10mg/day for 8 weeks p.o. rabeprazole 10mg/day p.o. for 8 weeks rebamipide 300mg/day p.o. for one year

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with early gastric cancer or gastric adenoma which were en bloc resected by endoscopic submucosal dissection

Exclusion criteria

Exclusion criteria: (1) Pregnant, possible pregnant, breast-feeding women (2) Patients with allergy for the test drugs (3) Patients with serious complications (4) Patients who are taking NSAIDs including COX-2 selective inhibitors, low dose aspirin and steroids (5) When gastric neoplasms are resected in a piecemeal fashion (6) When further treatment such as second ESD or surgery is required after the first ESD

Design outcomes

Primary

Measure	Time frame
Cure rates of gastric ulcer at 4 and 8 weeks of the treatment	—

Secondary

Measure	Time frame
safety, influence of CYP2C19 genetic polymorphism, incidence of metachronous gastric cancer	—

Countries

Japan

Contacts

Public ContactKazuhiko Nakamura

Kyushu University Department of Medicine and Bioregulatory Science

092-642-5286

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026